Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 21, 2024

Efficacy and Safety of Vunakizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Journal of the American Academy of Dermatology

 

Additional Info

Journal of the American Academy of Dermatology
Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial
J Am Acad Dermatol 2024 Sep 25;[EPub Ahead of Print], K Yan, F Li, X Bi, L Han, Z Zhang, R Chen, Y Li, L Zhang, X Wang, L Li, J Lu, A Xu, S Yang, Y Lu, J Sun, Z Li, X Zhu, M Jiang, S Zhang, W Wang, Y Li, Z Meng, H Li, K Mou, X Han, S Li, A Chen, X Li, D Liu, C Zhang, C Ji, Y Wang, H Cheng, X Cui, X Yao, X Bai, G Dong, J Xu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading